The Oxford AstraZeneca combine COVID-19 vaccine development is at a later stage of the trial, and the results are awaited.
The Oxford AstraZeneca combine COVID-19 vaccine development is at a later stage of the trial, and the results are awaited.On April 30, 2020, AstraZeneca and the University of Oxford had announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19. The vaccine candidate AstraZeneca is already in large-scale Phase III human trials to assess whether it can protect against COVID-19. The results of the Oxford Covid-19 vaccine study will be out on July 20. Interestingly AstraZeneca’s AZD1222 is the most advanced vaccine in terms of development accordingly to WHO chief scientist.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.
Copied!